#USA #Santa Cruz #Medical Device #Emboline #Emboliner

Emboline Launches the Emboliner® Embolic Protection System in the U.S.

On October 2, 2026, Emboline, Inc., a cutting-edge medical technology firm, proclaimed a pivotal step in its history with the introduction of the Emboliner® Embolic Protection System for commercial use in the United States. This announcement not only signifies a leap forward for the company but also for the broader medical community seeking advanced solutions for embolic protection.

The Emboliner represents a revolutionary approach to managing embolic debris during transcatheter interventions, particularly during procedures such as transcatheter aortic valve replacements (TAVR). The first deployment of this technology took place during two TAVR procedures, overseen by Dr. Tamim Nazif, Co-Director of the Structural Heart and Valve Center at New York-Presbyterian/Columbia University Irving Medical Center. Patients and physicians alike will benefit from this novel system, designed to capture and eliminate debris that could lead to serious complications, including strokes.

In September 2026, the Emboliner received clearance from the U.S. Food and Drug Administration (FDA) under the 510(k) premarket notification process. Scott Russell, CEO of Emboline, expressed pride in reaching this milestone so swiftly, highlighting the collaborative efforts of Dr. Nazif and the New York-Presbyterian/Columbia team in initiating this commercial introduction. Russell stated, "Completing the first commercial Emboliner procedures in the U.S. represents a defining milestone for Emboline and brings a new embolic protection option to physicians and their patients."

Dr. Nazif shared insightful perspectives regarding the clinical implications of the Emboliner. He emphasized that the persistent concerns surrounding stroke and the risks posed by embolic debris during TAVR indicate a crucial need for a more comprehensive and sophisticated embolic protection approach. The knowledge gained from the PROTECT H2H clinical trial, which involved the Emboliner technology, has shown promising results and underscored the potential benefits of this new system in clinical settings.

Emboline, founded in Santa Cruz, California, maintains a mission to develop pioneering medical technologies that aim to reduce embolic complications in cardiovascular procedures. The Emboliner's innovation lies in its ability to provide full cerebral and systemic embolic protection, effectively capturing debris before it can traverse to critical areas like the brain or other vital organs.

The strategy for the U.S. market launch will be methodical and controlled, with particular emphasis on established structural heart centers as initial sites for deployment. This approach is designed to ensure that both healthcare providers and patients experience the maximum utility and safety from the Emboliner technology right from the start.

Furthermore, Emboline's technological advancements derive from extensive research and intellectual contributions from its founder, Dr. Amir Belson. Known for his entrepreneurial expertise, Dr. Belson has previously founded several companies in the medical technology sphere, setting a strong foundation for Emboline's commitment to innovation and quality.

The introduction of the Emboliner not only enhances the options available to healthcare professionals but also stands to improve patient outcomes by mitigating the risks associated with embolic debris during heart valve interventions. Emboline's efforts are a testament to the relentless pursuit of knowledge and improvement within the medical technology landscape, making a significant impact in the fight against embolic complications.

With the launch of the Emboliner, Emboline is poised to change the landscape of cardiac interventions and usher in a new era of embolic protection that prioritizes patient safety and improved clinical outcomes. The medical community watches with anticipation as this technology begins to transform the standard of care in structural heart procedures across the nation.